经皮冠状动脉血运重建:JACC历史性突破视角
然而,在多支病变和无保护左主干病变患者中,经皮冠状动脉介入与冠状动脉旁路移植术的角色仍难以确立,多项关键试验和荟萃分析基于缺血综合征类型、冠状动脉解剖和患者整体合并症比较了两种策略。个体化预后精准医学正成为选择治疗的重要方法,但技术和新型药物的持续进步将继续促使我们重新思考「哪种治疗策略更好且适用于哪位患者」。
要点
- 经皮冠状动脉介入已成为晚期冠心病可接受的治疗选择。
- 多支病变和无保护左主干病变中,经皮冠状动脉介入与冠状动脉旁路移植术的角色仍待明确。
- 个体化预后精准医学正成为选择血运重建策略的重要方法。
核心结论
- 多支病变和无保护左主干病变患者中,经皮冠状动脉介入与冠状动脉旁路移植术的相对角色仍未完全确立。
- 个体化预后精准医学正成为选择治疗策略的重要方法。
主要发现
- 多项关键试验和荟萃分析基于缺血综合征类型、冠状动脉解剖和患者整体合并症比较了经皮冠状动脉介入与冠状动脉旁路移植术。
- 技术和新型药物的持续进步将继续促使重新思考治疗策略选择问题。
临床怎么用
- 临床选择血运重建策略时需综合考虑缺血综合征类型、冠状动脉解剖和患者整体合并症。
- 个体化预后精准医学可用于辅助选择经皮冠状动脉介入或冠状动脉旁路移植术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last 4 decades, percutaneous coronary intervention has evolved dramatically and is now an acceptable treatment option for patients with advanced coronary artery disease. However, trialists have struggled to establish the respective roles for percutaneous coronary intervention and coronary artery bypass graft surgery, especially in patients with multivessel disease and unprotected left-main stem coronary artery disease. Several pivotal trials and meta-analyses comparing these 2 revascularization strategies have enabled the relative merits of each technique to be established with regard to the type of ischemic syndrome, the coronary anatomy, and the patient's overall comorbidity. Precision medicine with individualized prognosis is emerging as an important method of selecting treatment. However, the never-ending advancement of technology, in conjunction with the emergence of novel pharmacological agents, will in the future continue to force us to reconsider the evolving question: "Which treatment strategy is better and for which patient?"
引用
- Serruys PW, Ono M, Garg S, et al. Percutaneous Coronary Revascularization: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol. 2021. PMID: 34294273. doi:10.1016/j.jacc.2021.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。